Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
ORIGINAL PAPER
Prevalence of antinuclear autoantibodies in patients with Raynaud’s phenomenon
Online publication date: 2010-12-20
Reumatologia 2010;48(6):391-395
KEYWORDS
ABSTRACT
Raynaud’s phenomenon occurs as a result of the exposure to low temperatures and stress. As a secondary phenomenon it coexists with connective tissue diseases: systemic sclerosis, systemic lupus erythematosus and dermatomyositis. Assessment of presence of autoantibodies is a non-invasive method, without any risk, which can be helpful in diagnosing patients with Raynaud’s phenomenon. The aim of the study was to measure the prevalence of autoantibodies in patients with Raynaud’s phenomenon. 76 patients with the diagnosed Raynaud’s phenomenon have undergone clinical and laboratory examinations. The paper presents results of clinical and laboratory studies of the observed patients.
REFERENCES (25)
1.
Le Roy EC, Medsger TA Jr. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485-488. .
2.
Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptom Raynaud’s phenomenon in general practice. Br Med J 1990; 301: 590-592. .
3.
Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in prevalence of symptom Raynaud’s phenomenon: a 5 region comparision. J Rheumatol 1997; 24: 879-889. .
4.
Silman AJ, Black CM, Welsh KI. Epidemiology, demographics, genetics. In: Systemic sclerosis, Clements PJ, Furst DE (eds). Williams&Wilkins, Baltimore 1996; 2: 23-50. .
5.
Kallenberg CG. Early detection of connective tissue disease in patients with Raynaud’s phenomenon. Rheum Dis Clin North Am 1990; 16: 11-30. .
6.
Spencer-Green G. Outcomes in primary Raynaud’s phenomenon: a meta-analysis and the frequency, rates and predictors of transition to secondary disease. Arch Intern Med 1998; 158: 595-600. .
7.
Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 75-91. .
8.
Boyd RL, Wilson TJ, Van De Water J, et al. Selective abnormalities in the thymic microenvironment associated with avian scleroderma, an inherited fibrotic disease of L200 chickens. J Autoimmun 1991; 4: 369-380. .
9.
Furst DE. The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary? [editorial]. J Mal Vasc 1999; 24: 95-98. .
10.
Clements PhJ, Furst DE (eds). Systemic sclerosis (textbook). Williams&Wilkins, Baltimore 1966. .
11.
Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351: 559-562. .
12.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576. .
13.
Herrick AL. Patogenesis of Raynaud’s phenomenon. Rheumatology 2005; 44: 587-596. .
14.
Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996; 347: 1453-1458. .
15.
Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158: 595-600. .
16.
Kallenberg CG. Overlapping syndromes, undifferentiated connective tissue disease, other fibrosing conditions. Curr Opin Rheumatol 1995; 7: 568-573. .
17.
Chen ZY, Silver RM, Ainsworth SK, et al. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984; 77: 812-822. .
18.
Weiner ES, Hildebrandt S, Senecal JL, et al. Prognostic significance of anticentromere antibodies and anti- topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991; 34: 68-77. .
19.
Sarkozi J, Bookman AA, Lee P, et al. Significance of anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 1987; 83: 893-898. .
20.
Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early differentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118: 602-609. .
21.
Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with various extent of skin sclerosis. J Rheumatol 1986; 13: 911-916. .
22.
Bryan C, Knight C, Black CM, et al. Prediction of five-year survival following presentation with scleroderma. Development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-2665. .
23.
Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533. .
24.
Medsger TA Jr, Masi AT, Rodnan GP, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-376. .
25.
Altman RD, Medsger TA Jr, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-413.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
